• I have pioneered the use of the PET– ligand and biomarker [11C](R)-PK11195 PET for activated microglia to examine the role of neuro-inflammation in parkinsonian disorders in vivo. The approach has been used in idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. It has been possible to demonstrate a disease pattern in vivo that closely corresponds with the known neuropathology in these disorders We have also been able to obtain longitudinal data over 2 years with this approach in idiopathic Parkinson’s disease, showing that microglial activation seems to change very little during this time. Recently I have used [11C](R)-PK11195 PET to demonstrate the effect of minocycline on microglial activation in a clinical study with MSA patients the first interventional study using this PET technique.
• My current imaging research concentrates on further examining of the role of microglial activation in neurological and psychiatric disorders using the very sensitive high resolution HRRT PET scanner as well as using different PET and MR modalities to correlate metabolic and structural changes with clinical presentations in dementia syndromes
• The focus of my clinical research is the clinical characterization of neurodegenerative disorders in correlation to genetic, biochemical and neuropathological parameters.